AAP News Vol. 13 No. 2 February 1997, p. 1
© 1997 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hegland, A.
Right arrow Search for Related Content

Next Article 

Future bright for more DTaP vaccines, expanded combinations

Anne Hegland

A flurry of activity in the development and licensing of DTaP (diphtheria-tetanus-acellular pertussis) vaccines coincides with the Academy's release of a related policy statement, recommending the use of acellular over the whole-cell vaccine (DTwP) for the initial series in infants and children. These events may bode well for DTaP's potential use in adults and for the future availability of more combined vaccines.

The most recent event came at the close of 1996, with licensure of the first DTaP product for use in all five doses in the DTP immunization series. Licensed by Wyeth-Leder-le Vaccines and Pediatrics, the use of Acel-Imune (Diptheria and Tetanus Toixoids and Acellular Pertussis Vaccine Adsorbed), has been expanded to include infants at 2, 4 and 6 months of age. Until now, Acel-Imune had been approved for booster use in the fourth and fifth doses in children who had received the whole-cell vaccine in the first three doses.